Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pfizer Inc. is conducting a clinical study titled ‘EPIC-Peds’ to evaluate the safety, pharmacokinetics, and efficacy of the drug combination nirmatrelvir/ritonavir in non-hospitalized pediatric patients with COVID-19 who are at risk of severe disease. The study aims to provide insights into how these drugs work in the body and their effectiveness in preventing disease progression.
The intervention involves administering nirmatrelvir and ritonavir, both antiviral drugs, to children and adolescents under 18 years old. The treatment is given orally, either as tablets or powder, twice daily for five days.
This interventional study is open-label, meaning both researchers and participants know the treatment being given. It follows a single-group assignment model without randomization, focusing primarily on treatment outcomes.
The study began on March 7, 2022, and is currently recruiting participants. The latest update was submitted on July 16, 2025. These dates are crucial for tracking the study’s progress and expected completion.
The outcome of this study could significantly impact Pfizer’s market position, potentially boosting its stock value if results are positive. It could also influence investor sentiment and competitive dynamics in the pharmaceutical industry, especially among companies developing COVID-19 treatments for children.
The study is ongoing, with further details available on the ClinicalTrials portal.